The New Way to
Who We Are
NangioTx team is made up of qualified experts in with extensive experience.
Founders Dr. Kumar (CEO) a Bioengineer & Dr. Hartgerink (CTO) a Chemist have over 35 years of biomedical-research experience and produced over 100 publications in the areas of biomaterials and tissue engineering.
NangioTx is now building its team to translate V-10 into a therapeutic product. Leading the initiative for Investigational New Drug (IND) studies is Chief Scientific Officer (Dr. Karel Petrak).
NangioTx is currently located in the Heart of New York City.
Complementing our expertise, NangioTx has assembled a diverse advisory board with legal, financial, business, and scientific expertise. Noteworthy members include Richard Dixon, PhD (Texas Heart Institute, director of animal efficacy studies), and established vascular surgeons who have extensive experience in PAD clinical trials.